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Abstract: In order to investigate the SAR of Ezetimibe analogs for cholesterol absorption inhibitions, amide group and 
electron-deficient pyridine ring were introduced to the C-(3) carbon chain of Ezetimibe. Eight new derivatives of the 2-
azetidinone cholesterol absorption inhibitors have been synthesized, and all of them were enantiomerically pure. All the 
new compounds were evaluated for their activity to inhibit cholesterol absorption in hamsters, and most of them showed 
comparable effects in lowering the levels of total cholesterol in the serum. 
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1. INTRODUCTION 
Atherosclerotic coronary heart disease (CHD) has been 
the major cause of death and cardiovascular morbidity in the 
world [1]. The prominent risk factor associated with CHD 
was the elevation of serum cholesterol levels [2]. Well estab-
lished clinical treatment for CHD has focused on life style 
changes and the reduction of serum cholesterol. These reduc-
tions have been shown to correlate strongly with the de-
crease of CHD mortality and the reversal of atherosclerosis 
as evidenced by the regression of occlusion of coronary ar-
teries [3]. Pharmacologically these reductions have focused 
on the use of “statins” or HMG-CoA reductase inhibitors to 
affect both the biosynthesis of cholesterol and clearance 
mechanisms [4]. The other major contributor to serum cho-
lesterol is from exogenous (dietary) or intestinal sources (en-
terohepatic circulation of biliary cholesterol). Blocking intes-
tinal sources of cholesterol represents a scientifically and 
pharmacologically interesting mechanism for affecting se-
rum cholesterol as it complements existing therapies in the 
clinic [5]. 
Ezetimibe(1) (Fig. 1), which was approved in late 2002 
for use either alone or in combination with a statin, was the 
only example to date of a drug that involves inhibition of 
intestinal cholesterol absorption [6]. A recent report from the 
Schering-Plough  Research Institute has described the dis-
covery of Niemann-Pick  C1 Like 1 (NPC1L1) protein as 
critical for the intestinal absorption of cholesterol. Knockout 
mice lacking the NPC1L1 gene showed markedly reduced 
cholesterol absorption and were no longer sensitive to further 
reduction of cholesterol absorption by ezetimibe. Thus 
NPC1L1 lies in the ezetimibe sensitive pathway for choles-
terol absorption, making it a likely candidate for the target of 
ezetimibe [7]. 
The reported structure-activity relationships (SAR) stud-
ies revealed that the 2-azetidinone was required for activity,  
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the C-(3) sidechain was optimal at three linking atoms bear-
ing a pendent aryl group and the C-(4) aryl residue was re-
quired and was optimally substituted with a polar moiety at 
the para position, the N-aryl ring was also required and was 
tolerant of a wide variety of substitutions [8-10]. It is known 
that bioisosterism is an important lead modification approach 
that has been shown to be useful to attenuate toxicity or to 
modify the activity of a lead, and many have a significant 
role in the alteration of pharmacokinetics of a lead. In order 
to investigate the effect of the polarity of the C-(3) sidechain 
on cholesterol absorption inhibition, we used bioisosteric 
interchange and introduced amide group to the C-(3) carbon 
chain in compounds 2a-d, increasing the polarity of C-(3) 
sidechain. The relative configuration at C-(3) and C-(4) of 
compounds 2a-d were all (3R, 4S). On the other hand, an-
other chemical modification of 1 in our research was elec-
tron-deficient pyridine ring and ester group to the C-(3) car-
bon chain in compounds 3a–d. As a result, the ezetimibe 
analogs 2a-d and 3a-d (Fig. 1) were designed, synthesized 
and their ability to inhibit cholesterol absorption was evalu-
ated [11]. 
2. RESULTS AND DISCUSSION 
2.1. Chemistry 
The synthetic route to 2a-d is summarized in Scheme 1 
[12]. Refluxing glutaric anhydride (4) with an equivalent 
amount of anhydrous MeOH afforded monomethyl glutarate 
(5), and treatment of 5 in refluxing SOCl2 yielded methyl 4-
(chloroformyl)butyrate (6) in excellent yield 84.9% without 
further purification. Reactions of methyl 4-
(chloroformyl)butyrate (6) with (S)-(+)-4-phenyl-2-
oxazolidinone in the presence of Et3N in anhydrous CH2Cl2
at room temperature gave intermediate 7. Reaction of a sub-
stituted aromatic aldehyde 8 with a substituted aromatic 
amine 9 in refluxing isopropyl alcohol gave imines 10. Then, 
intermediate 7 was treated with TiCl4, Hünig’s base, and the 
corresponding imine 10 to give the intermediate  -
aminoxazolidinone 11. The major diastereomer was purified 
to homogeneity by crystallization and then cyclized in two 
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(BSA) followed by treatment with a catalytic amount of 
tetrabutylammonium fluoride (TBAF) to get a single enanti-
omerically pure intermediate 12. Then hydrolysis and amida-
tion of 12 led to enantiomerically pure 2-azetidinone analogs 
2a-d.
The synthesis of target compounds 3a-d is summaried in
Scheme 2. The intermediate 12 was used as started material. 
Preparation of alcohol 14 was the key step in synthesis of 
target compounds because the  -lactam ring would be 
opened by reductive reagents. According to literature, 
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Fig. (1). The chemical structures of ezetimibe and analogs. 
O
O
O O
O
OH
OMe
O
O
Cl
OMe
N O
O
Ph
HN O
OMe
O
N
O
MeO
O
N
O
HO
O
N
O
N
H
O
R3
O N
O O
H3CO
O
Ph
NH2 CHO
N
HC
R2 R1
R1
R2
R2
R1
R1
R2
R1
R2
R1
R2
a b c
d
e
f g
h
4 5 67
89 1 0
11 12
13
2a-d
Scheme 1. Reagents and conditions: (a) CH3OH, reflux, 1h; (b) SOCl2, reflux, 2h; (c) (S)-(+)-4-phenyl-2-oxazolidinone, Et3N CH2Cl2, r t, 
5h; (d) iPrOH reflux, 2h; (e) TiCl4, DIPEA, CH2Cl2, -30- 40 , 4h; (f) BSA,TBAF, toluene, 40-50 , 4h; (g) LiOH, THF/H2O, r t, over-
night; (h) substituted aromatic amine or aliphatic amine, DCC/DMAP, CH2Cl2, r t, overnight. 502    Letters in Drug Design & Discovery, 2011, Vol. 8, No. 6 Wang et al.
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Scheme 2. Reagents and conditions: (a) LiOH, THF/H2O, r t, overnight; (b) NaBH4, I2, THF, reflux, 6h; (c) NaBH4, THF, reflux, 24h; (d) 
substituted aromatic acid, DCC/DMAP, CH2Cl2, r.t, overnight.
 -lactam compound 15 and 17 could undergo reductive 
opening in the presence of sodium borohydride in methanol 
or isopropanol (Fig. 2) [13-14]. At beginning, methyl ester 
12 was reduced by NaBH4 in THF as solvent at room 
temperature for 5h. Unfortunately neither the ester-reducing 
product nor ring-opening product was obtained, even when 
the reaction was warmed to reflux. After that the solvent was 
changed to methanol according to literature
12. It was ob-
served that methyl ester 12 was transformed to alcohol 14 in
yield of 12% along with the starting material in majority. 
The key intermediate 14 was not acquired from methyl ester 
12 in good yield, but these results were also encouraging to 
us, since it was found that the  -lactam ring in our com-
pounds were more stable comparatively, at least upon treat-
ment with NaBH4. It was known that reduction of carboxylic 
acids to alcohols was an important tansformation in synthetic 
organic chemistry and several methods were available for 
this purpose such as NaBH4-I2 in THF. So methyl ester 12
was first hydrolyzed by LiOH-H2O to give acid 13 in almost 
quantitative yield, and then reduced to obtain alcohol 13. In a 
typical procedure [15], the carboxylic acid 13 was added 
slowly to the suspension of NaBH4 in THF and the mixture 
stirred until gas evolution ceased. Iodine in THF was then 
added slowly at room temperature and then the contents were 
warmed to reflux for 1.5-2 h. The reaction was terminated at 
once the starting material disappeared basically. After the 
usual workup, the alcohol 14 was obtained in ideal yield. 
Finally the reaction of 14 with substituted aromatic acid in 
the presence of DCC/DMAP in anhydrous CH2Cl2 at room 
temperature gave 2-azetidinone derivatives 3a–d in good 
yields (60.8–66.4%). 
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Table 1.  Structures, Yields, Melting Points and of the Target Compounds 
Compd.
a R 1 R 2 R3 Yield, %  mp, 
2a 3,4-dioxolmethylene 4-Me  53.6 115－117 
2b 3,4-dioxolmethylene  4-Me  n-C3H7 41.8 235-237 
2c 3,4-dioxolmethylene  4-Me  62.4 155-157 
2d 4-OMe  4-OMe  65.0 oil 
3a 3,4-dioxolmethylene  4-Me 
N
52.1 98-101 
3b 3,4-dioxolmethylene-6-bromo-  4-Me 
N
42.6 oil 
3c 3,4-dioxolmethylene  4-Me 
N
52.3 120-122 
3d 3,4-dioxolmethylene  4-Me  47.3 118-120 
Table 2.  Spectral Data of the Target Compounds 
Compound Spectral Data 
2a. 
1HNMR (CDCl3): 1.43-1.96 (m,10H, -(CH2)5-), 2.03-2.23 (m, 2H, -CH2-CH2-)，2.32 (s, 3H, Me)， 2.52-2.65 (m, 2H, -CH2-CH2-), 3.06-
3.11 (m, 1H, -CH-CH-), 4.60 (s, 1H, -CHN-), 3.66-3.68(m, 1H, -CH-), 5.94 (2H, s, -OCH2O-), 6.77-6.87 (m, 3H, Ar-H), 7.03-7.17 (dd, 4H, 
Ar-H, J = 8.1Hz); MS (70eV) m/z: 435 ([M+H]
+)。Anal.calc. for: C26H30N2O4 (434.22): C 71.53 H 7.14 N 6.69; found : C 71.87 H 6.96 N 
6.45; []= -11.4 (C=0.33, D:589nm, T=20, solv:MeOH) 
2b 
1HNMR (CDCl3): 0.98-1.03 (m, 3H, -CH2CH2CH3), 1.43-1.64 (m, 2H, -CH2CH2CH3) 2.03-2.12 (m, 2H, -CH2-CH2-)，2.35 (s, 3H, Me)，
2.48-2.69 (m, 2H, -CH2-CH2-), 3.04-3.19(m, 2H, -CH2-), 3.24-3.43 (m, 1H, -CH-CH-), 4.87 (s, 1H, -CHN-), 5.94 (2H, s, -OCH2O-), 6.57-
6.67 (m, 3H, Ar-H), 6.95-7.18 (dd, 4H, Ar-H, J = 7.8Hz); MS (70eV) m/z: 417 ([M+H]
+); Anal.calc. for: C23H26N2O4 (394.19): C 70.29 H 
6.52 N6.97; found : C 70.03 H 6.64 N 7.10; []= -11.4 (C=0.055, D:589nm, T=20, solv:MeOH) 
2c
1HNMR (CDCl3): 1.59－1.73(m, 3H, -CH3), 1.92-2.08 (m, 2H, -CH2-CH2-)，2.29 (s, 3H, Ar-Me)， 2.39-2.49 (m, 2H, -CH2-CH2-), 2.86-
2.89 (m, 1H, -CH-CH-), 3.48-3.51 (m, 1H, -CHN-), 5.95 (2H, s, -OCH2O-), 6.56 (s, 1H, Ar-H), 7.01 (s, 1H, Ar-H), 7.14-7.30(m, 9H, Ar-H); 
MS (70eV) m/z: 557, 559 ([M+H]
+); Anal.calc. for: C28H28N2O4 (456.20): C 73.54 H 6.33 N6.27; found : C 73.66 H 6.18 N 6.14; []= -19.8 
(C=0.185, D:589nm, T=20, solv:MeOH) 
2d 
1HNMR (CDCl3): 2.31(s, 3H, -CH3), 2.24-2.30(m, 2H, -CH2-CH2-), 2.59-2.64 (m, 2H, -CH2-CH2-), 3.09-3.14 (m, 1H, -CH-CH-), 3.78 (s, 
6H, -OCH3), 4.66 (d, J = 2.0Hz, 1H, -CHN-), 6.76-6.85 (m, 4H, Ar-H), 7.19-7.27 (m, 4H, Ar-H), 7.28-7.40 (m, 4H, Ar-H), 7.79 (s, 1H, -
NH-CO-); MS (70eV) m/z: 445.4([M+H]
+); Anal.calc. for C27H28N2O4 (444.20): C 72.73 H 6.49 N 6.41; found : C 72.95 H 6.35 N 6.30; 
[]= +13.3 (C=0.34, D:589nm, T=20, solv:MeOH)
3a
1HNMR (CDCl3,300MHz)  : 1.96-2.17 (4H, m, -CH2-CH2-), 2.26 (s, 3H, -CH3), 3.11 ( 1H, m, -CH-CO), 4.38-4.40 (2H, t, -CH2OCO, 
J=5.4Hz), 4.57(1H, d, -CHN, J=2.1Hz), 5.95 (2H, s, -OCH2O-), 6.77-6.85 (3H, m, Ar-H), 7.034-7.191 (4H, dd, Ar-H, J=8.4Hz), 7.35-7.42 
(1H, m, Py –H
5), 8.27-8.30 (1H, d, Py –H
4, J=8.4Hz), 8.70-8.83 (1H, m, Py –H
6), 9.21 (1H, s , Py –H
2); MS (70eV) m/z : [M+H]
+445, 
[M+Na]
+467, [M+K]
+483; Anal.calc. for: C26H24N2O5 (444.17): C 70.53 H 5.27 N6.19; found : C 70.26 H 5.44 N 6.30; []= -15.6 
(C=0.215, D:589nm, T=20, solv:MeOH) 
3b 
1HNMR (CDCl3,300MHz)  : 2.16 (4H, m, -CH2-CH2-), 2.28 (s, 3H, -CH3 ), 3.10 ( 1H, m, -CH-CO), 4.43 (2H, s, -CH2OCO), 5.12 (1H, d, -
CHN, J=2.1Hz), 5.96 (2H, s, -OCH2O-), 6.72 (1H, s, Ar-H), 7.03-7.16 (5H, m, Ar-H), 7.37 -7.41(1H, m, Py –H
5), 8.27 (1H, d, Py –H
4,
J=8.4Hz), 8.78 (1H, s, Py –H
6), 9.20 (1H, s , Py –H
2); MS (70eV) m/z : [M+H]
+523.1, 525.1; Anal.calc. for: C26H23BrN2O5 (522.08): C 
60.02 H 4.21 N5.15; found : C 59.67 H 4.43 N 5.35;  
3c
1HNMR (CDCl3,300MHz)  : 1.90-2.12 (4H, m, -CH2-CH2-), 2.27 (3H, s, -CH3), 3.12 ( 1H, s, -CH-CO), 4.40 (2H, s, -CH2OCO), 4.58(1H, s, 
-CHN), 5.95 (2H, s, -OCH2O-), 6.77-6.86 (3H, m, Ar-H), 7.04-7.191 (4H, dd, Ar-H, J=8.1Hz), 7.82-7.84 (2H, d, Py –H, J=4.5Hz), 8.79 
(2H, s , Py –H); MS (70eV) m/z : [M+H]
+445, [M+Na]
+467, [M+K]
+483; Anal.calc. for: C26H24N2O5 (444.17): C 69.91 H 5.68 N6.41; 
found : C 70.26 H 5.44 N 6.30; []= -25.2 (C=0.17, D:589nm, T=20, solv:MeOH) 
3d 
1HNMR (CDCl3,300MHz)  : 1.94-2.12 (4H, m, -CH2-CH2-), 2.27 (3H, s, -CH3), 3.12 ( 1H, s, -CH-CO), 4.35－4.37 (2H, d, -CH2OCO, 
J=5.4Hz), 4.58(1H, s, -CHN), 5.94 (2H, s, -OCH2O-), 6.77-6.86 (3H, m, Ar-H), 7.04-7.195 (4H, dd, Ar-H, J=8.4Hz), 7.41-7.46 (2H, m, Ar-
H), 7.54-7.58 (1H, m, Ar-H), 8.00-8.03 (2H, d, Ar-H, J=7.8Hz); MS (70eV) m/z : [M+H]
+444, [M+Na]
+466, [M+K]
+482; Anal.calc. for: 
C27H25NO5 (443.17): C 73.34 H 5.47 N3.03; found : C 73.12 H 5.68 N 3.16; []= -28.3 (C=0.075, D:589nm, T=20, solv:MeOH) 504    Letters in Drug Design & Discovery, 2011, Vol. 8, No. 6 Wang et al.
Table 3.  Cholesterol Absorption Inhibiton of New Analogs and Reference Compounds in Orally Dosed Seven Day Cholesterol Fed 
Hamsters 
Compd.
a TC
b(% reduction)  HDL-C
c(% increase) 
2a NE
d NE
d
2b NE
d NE
d
2c 27.3*  24.9 
2d 28.1*  21.7 
3a 39.8*  32.6* 
3b 31.9*  28.4* 
3c 26.7  19.2 
3d 20.3  25.9 
Ezetimibe 48.7**  37.3** 
**P < 0.01; *P < 0.05. 
a6-8 hamsters per group; Dose: 50 mg/kg. 
bReduction of total cholesterol comparing to the one in animals fed by high-cholesterol diets. 
cIncrease of HDL-C comparing to the one in animals fed by high-cholesterol diets. 
dNE: no effect.
The structures and spectral characteristics of the target 
compounds 2a-d and 3a-d were mentioned in Table 1 and 
Table 2.
2.2. Biological Studies 
Cholesterol absorption inhibition was assessed in orally 
dosed, cholesterol-fed hamsters as reported in literature [16]. 
The result is presented in the Table 3. As can be seen from 
the data, most of the new compounds demonstrated moderate 
effect in lowering the total cholesterol in serum, especially 
compound 2c 2d 3aand 3b, although their potency was still 
somewhat below that of ezetimibe. Compound 2a and 2b
have no effect in lowering the total cholesterol in serum. It 
was also found that 3a and 3b could raise high-density lipo-
protein cholesterol (HDL-C) levels markedly. This activity 
may be good for prevention and treatment of CHD. The cur-
rent work suggests that the amide group in the C-(3) side 
chain was not critical for the cholesterol absorption inhibi-
tion activity and a pendent aryl group at the C-(3) sidechain 
was required. From the activity of 3a-d in raising the HDL-C 
in serum, it was suggested that nicotinic acid may be crucial 
for raising high-density lipoprotein cholesterol. These SAR 
trends may provide insights into the further design of novel 
cholesterol absorption inhibitors. 
3. CONCLUSIONS 
In an effort to understand the SAR around cholesterol ab-
sorption inhibition, eight 2-azetidinone derivatives were syn-
thesized and all of them were enantiomerically pure. Their 
cholesterol absorption inhibition activities were evaluated.  
Most of them showed comparable effects in lowering the 
levels of total cholesterol in the serum. These information 
could be valuable for further investigation of SAR and will 
be useful in later research of cholesterol absorption inhibi-
tors. 
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